



## New Development of DNA and mRNA Vaccines against Infectious Diseases

Guest Editor:

### Dr. Takashi Imai

1. Department of Microbiology,  
Saitama Medical University,  
Saitama, Japan  
2. Department of Infectious  
Diseases and Host Defense,  
Gunma University, Gunma, Japan

Deadline for manuscript  
submissions:  
**closed (30 September 2022)**

### Message from the Guest Editor

Dear Colleagues,

Antibiotics and vaccines have been the most effective defense against pathogens since human beings first discovered “how to fight against infectious disease”. Vaccination technology is evolving day by day. Nucleotide-based vaccines, DNA vaccines and mRNA vaccines are the newest vaccine platforms, and the latest commercialized “mRNA vaccine” has been distributed all over the world as the “savior of COVID-19”. This vaccine is a game changer, but there is some concern regarding its need for deep-freezer storage. Compared with mRNA vaccines, DNA vaccines can be stored more stably.

This Special Issue will focus on “DNA vaccine and mRNA vaccine against Infectious Diseases”. It is not limited to original papers: review articles, new methodologies, concepts for new DNA or mRNA vaccines and next-generation vaccines against infectious diseases affecting humans, animals and plants are also welcome.

Dr. Takashi Imai  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)